Precision Oncology Resources: Webinars
Sponsored by Millipore Sigma
This webinar will address the need for innovation in the early detection of cancer and the approach taken by Elypta, a Swedish cancer detection firm, to develop new metabolism-based biomarkers.
Elypta was funded by the EU Horizon 2020 program to bring the first kidney cancer recurrence test to market. Elypta’s approach is based on profiling glycosaminoglycans — or the GAGome — and developing scores indicative of cancer. At the 2021 American Society of Clinical Oncology conference, a proof-of-concept study across 14 cancer types revealed the broader potential for early detection using the technology, highlighting the sensitivity to stage I disease.
Karl Bergman, CEO of Elypta, will discuss the need for new cancer biomarkers and Elypta’s results highlighting the potential of glycosaminoglycans as a tool in early detection. He will also outline the path Elypta took to develop their research-use-only (RUO) kits, partnering with MilliporeSigma at an early stage to ensure a clear path to large-scale in vitro diagnostic (IVD) manufacturing and enabling the Elypta team to focus their efforts on research and development.
Michael Mitchell, commercial project manager at MilliporeSigma, will discuss the milestones and challenges of MilliporeSigma’s work with Elypta. Mitchell will cover highlights from the set-up, pilot, and engineering phases of Elypta’s RUO cancer detection kit, as well as the preparative work for their IVD offering.
Attendees will learn:
- Why more biomarkers are needed for the earliest stages of cancer
- Key aspects and results from the GAGome-based liquid biopsy platform developed by Elypta
- How a partnership with MilliporeSigma helped Elypta in the development journey
Sponsored by Agena Bioscience
This webinar will provide an overview of how liquid biopsies – the molecular analysis of circulating cell-free tumor DNA (ctDNA) released into the blood - can provide new insights into tumor biology and help personalize patient care.
Klaus Pantel, Chairman of the Institute of Tumor Biology at University Medical Center Hamburg-Eppendorf, will discuss how liquid biopsy analyses can provide information for the early detection of cancer and identify cancer patients at risk of relapse. The approach may also serve to monitor tumor evolution, therapeutic targets, or mechanisms of resistance on metastatic cells.
Liquid biopsies show particular promise for metastatic cancers. Repeated needle biopsies of metastatic lesions are invasive and some locations are difficult to access. In contrast, monitoring of blood samples is only minimally invasive and can identify tumor evolution and tumor subtype switches, which may then lead to the selection of appropriate therapies based on the molecular composition of recurrent metastases.
Prof. Pantel will also discuss the importance of technical standardization and clinical validation of liquid biopsy assays.
Dr. Alexander Sartori from Agena Bioscience will follow with an overview of Agena’s MassArray System and available variant panels for circulating cell-free DNA in various cancers.
Sponsored by Natera
The recent publication of IMvigor010 trial data demonstrates the strength of circulating tumor DNA (ctDNA) testing post-cystectomy in muscle-invasive bladder cancer (MIBC) to help identify patients likely to benefit from immunotherapy. The data analysis demonstrated both the prognostic and the predictive value of molecular residual disease (MRD) testing in this patient population. In this webinar, Thomas Powles, professor of genitourinary oncology and director of the Barts Cancer Centre, will share the findings of the IMvigor010 data analysis, present relevant MIBC publications, and discuss the IMvigor011 Phase III trial.
Join the discussion of this and other potential applications of ctDNA in urothelial carcinoma:
- Surveillance monitoring with ctDNA could allow for earlier detection of relapse on a molecular level and potentially allow clinicians to treat patients at low levels of disease burden.
- Treatment response monitoring of MRD could predict outcomes as early as week six into adjuvant therapy.
- Post-TURBT treatment decisions for Stage I or lower patients could be enhanced by assessing MRD.
- Further research of ctDNA testing in the neoadjuvant setting in bladder cancer could potentially create a pathway for Stage II and Stage III patients to avoid cystectomy.
Sponsored by Akoya Biosciences
The I-SPY 2 (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis) is an adaptive clinical trial platform that supports the rapid, focused clinical development of paired oncologic therapies and biomarkers. The goal is to identify improved treatment regimens based on the molecular characteristics of individual patients’ disease.
In this webinar, Drs. Laura Esserman and Michael Campbell will discuss the I-SPY 2 trial of neoadjuvant treatment for locally advanced breast cancer. The trial involved the use of Multiplex Immunofluorescence (mIF) based biomarker panels, developed with the Akoya Phenoptics platform, to map the heterogeneity of the tumor microenvironment.
Drs. Esserman and Campbell have standardized biomarker discovery and development efforts on the Phenoptics platform to measure as many as six markers at a time on a single pathology slide using multiplex immunofluorescence. They will discuss how I-SPY 2 has the potential to significantly accelerate the time to get effective treatments to the patients who will benefit, while also reducing the cost of drug development.
In this talk, attendees will:
- Learn how the I-SPY 2 trial’s innovative adaptive trial design has accelerated the pace of new drug development in oncology through improved clinical trials and biomarker use for breast cancer.
- Understand the value of spatial biomarkers and their use in the I-SPY trials to serve as predictors of response to immuno-oncology drug combinations.
- Learn how fundamental innovations deriving from the I-SPY 2 trial are improving clinical trials and patient care on many levels and how a number of these advances have become best practices.
Sponsored by 10x Genomics
This webinar will discuss the applications of spatial transcriptomics for elucidating the molecular mechanisms of immunotherapy response as well as the pathogenesis of SARS-CoV-2.
Arutha Kulasinghe, Spatial Biology Group Leader at the University of Queensland, will discuss recent advances in the use of spatial transcriptomics, which provides unprecedented insights into tissue architecture and cellular activation status.
Dr. Kulasinghe will provide an overview of spatial genomics and proteomics as well as the landscape of current technologies and applications in basic and clinical research. He will also discuss two recent studies from his team: one that applied spatial transcriptomics to identify predictive biomarkers for immunotherapy and another that used spatial transcriptomics to identify host response signatures in patients infected with SARS-CoV-2. These studies highlight the use of spatial transcriptomics for biomarker discovery approaches.
Dr. Kulasinghe will also address future directions and applications for spatial biology in translational research and pathology.
Sponsored by Akoya Biosciences
MITRE Study: Standardizing Spatial Phenotyping and Biomarker Analysis with Multiplexed Immunofluorescence in Immuno-Oncology
In this webinar, Dr. Bernard Fox and Elizabeth Engle will discuss the results of the Multi-Institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE Study), published in the Journal for ImmunoTherapy of Cancer (JITC) in July 2021. The MITRE study is the first multi-institutional study involving multiplexed immunofluorescence (mIF) designed to develop and validate a spatial biology workflow that is transferable among sites and delivers site-independent and reliable quantitative data for immunotherapy research. The MITRE results are an important step toward standardizing an automated mIF-based spatial biology workflow that provides the level of performance needed to support clinical trials and that can be applied to clinical testing in the future.
In this talk, attendees will:
- Review evidence that evaluating the immune landscape of cancer can inform a patient’s prognosis and provide predictive biomarkers for response to therapy.
- Learn about the MITRE study and the evidence it provides on the standardization of an automated spatial biology workflow for clinical and translational research.
- Understand the value of spatial biomarkers and how they allow researchers to map the interactions of tumor and immune cells across an entire tumor tissue section without destroying the spatial context of the tissue, enabling a more accurate assessment of tumor-immune biology.
- Learn how the Phenoptics mIF solution is being used by researchers to develop spatial biomarkers for trials and eventual clinical use.
Sponsored by BD
Multiomic Analysis of Immune Regulation in Triple-Negative Breast Cancer Points to New Therapeutic Strategies
Checkpoint inhibitors have revolutionized cancer treatment, but only a small proportion of breast cancer patients have shown benefit from immunotherapy. One of the factors limiting the effect of immunotherapies is the presence of tumor-educated immunosuppressive myeloid populations that inhibit anti-cancer T-cell cytotoxic killing activity.
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous and poorly defined group of tumor-infiltrating myeloid progenitors that contribute to cancer progression and metastasis. MDSCs are a compelling target for cancer therapy, but their high heterogeneity and poor definition hamper the development of anti-cancer MDSC-based therapy.
In this webinar, David Gallego Ortega of the University of Technology Sydney School of Biomedical Engineering will discuss a study that used single-cell RNA-seq in mouse models of triple-negative breast cancer (TNBC) to create a spatiotemporal atlas of inflammation associated with metastatic breast cancer cell dissemination. This high-resolution map of the cellular composition and functional diversity of inflammatory cells identified a subclass of granulocytic MDSCs involved in the formation of the pro-metastatic niche and progression to metastatic disease.
Dr. Ortega’s team further characterized this pro-metastatic MDSC subclass integrating a high-dimensional cell surface antibody panel (18 FACS antibodies + 91 AbSeq antibodies) to the single-cell whole-transcriptome profiling of MDSCs to uncover immunosuppressive pathways and molecular targets with potential therapeutic value.
This high-resolution multiomic definition of pro-metastatic MDSCs is a step forward for designing new strategies to efficiently reprogram immunosuppressive cell populations and stimulate antitumor immunity, ultimately paving the way for the development of the next generation of immunotherapy for aggressive breast cancer.
Learning objectives include:
- Building a spatiotemporal atlas for deep characterisation of cell states during the pre-metastatic niche formation at the single-cell level
- Integrating a high-dimensional cell surface antibody panel (18 FACS antibodies + 91 AbSeq antibodies) and single-cell whole-transcriptome profiles of protumorigenic MDSCs
- Designing new strategies to efficiently reprogram immunosuppressive cell populations and stimulate antitumor immunity
Sponsored by Thermo Fisher Scientific
Institutional Lessons From Implementing Plasma Genotyping to Monitor Response and Treatment in Non-Small Cell Lung Cancer
Nearly 70 years after the discovery of cell-free DNA, plasma genotyping is routinely used to non-invasively detect and quantify clinically relevant point mutations, insertions/deletions, amplifications, rearrangements, and aneuploidy. Over the past eight-plus years, strong concordance has been shown between plasma and tissue-based genomic assays, encouraging the clinical adaptation of plasma genotyping. In this webinar, Dr. Cloud Paweletz will present institutional experiences implementing liquid biopsies into non-small cell lung cancer. He will discuss technical limitations and lessons learned with a particular focus on minimal residual disease, treatment response, and the emergence of resistance monitoring. The realization of these lessons, however, spurs significant investment in techniques and technologies to increase specificity and sensitivity and reduce turnaround time and cost for further clinical adoption of this promising diagnostic.
In 2018, there were an estimated 61,698 people with chronic myeloid leukemia (CML) in the United States, according to the National Institutes of Health. Even though advances in treatment and care have transformed CML into a manageable disease, several significant challenges remain in monitoring therapeutic response and disease progression.
Please join us on October 19th to discuss CML and the importance of accurate and fast monitoring with two speakers, Dr. Bijal Parikh and Dr. Yitz Goldstein. Dr. Parikh is the Medical Director of the Barnes-Jewish Hospital Molecular Diagnostics Laboratory and Associate Medical Director of the Molecular Infectious Disease and HLA Laboratories. Dr. Goldstein is the Director of the Genomic Laboratories at Montefiore Medical Center and the Director of Clinical Virology.
The discussion will touch on the revolution of Tyrosine kinase inhibitors and their resistance, the current CML guidelines, and the clinical impact of different assays. Additionally, our speakers will provide a first-hand perspective on the clinical value of rapid molecular CML monitoring and its effect on patient care.
Sponsored by Akoya Biosciences
In this webinar, Dr. Kurt Schalper, director of the Translational Immuno-oncology Laboratory at the Yale Cancer Center, will discuss the immune composition and therapeutic implications in human non-small cell lung cancer (NSCLC), focusing on dominant immune evasion pathways and T-cell dysfunction. He will present results from studies using genomic and spatially resolved analysis of different cell types, targets, and pathways that have shed light on the complexity of tumor/immune cell interactions and their role in sensitivity and resistance to immunostimulatory anti-cancer therapies. He will also discuss the potential application of these concepts for future biomarker development and novel treatment strategies.
- Discuss the role of the tumor microenvironment in tumor progression and therapeutic resistance.
- Learn about the dominant mechanism of immune evasion and immunotherapy response in human NSCLC.
- Understand the current landscape of immunotherapy biomarkers and the contribution of spatially resolved analysis.
Sponsored by Akoya Biosciences
This multi-stakeholder panel discussion will bring together a diverse set of experts who will highlight innovative solutions that demonstrate the integral role of spatial biomarkers in immuno-oncology. Learn about their advancements from biomarker discovery to translational research, and how they are shaping the future direction of the spatial biology field.
In this talk, attendees will:
- Gain an understanding of the current limitations of predictive biomarkers in immuno-oncology
- Become familiar with the different perspectives on the value and important role of multiplex immunofluorescence (mIF) to improve biomarker strategies in immuno-oncology
- Learn about the future direction of spatial biomarkers in translational research & precision medicine
The presenters on this panel are Gavin Gordon, MBA, PhD, vice president, clinical market developmen at Akoya Biosciences, Laura Esserman, MD, MBA, professor of surgery and radiology at University of California, San Francisco and director of the UCSF Carol Franc Buck Breast Care Center, Bernard A. Fox, PhD, harder family chair for cancer research, Robert W. Franz Cancer Center, Earle A. Chiles Research Institute at Providence Cancer Institute, Elizabeth L. Engle, MS., a senior Laboratory Manager at John Hopkins Hospital, Maryland, and Kurt Schalper, MD, PhD, translational immuno-oncology laboratory lead at Yale Cancer Center.